About
Minicircle develops non-viral, reversible plasmid gene therapies, such as follistatin, administered via subcutaneous injection at licensed international partner clinics to support muscle mass, body composition, and reduce epigenetic age; these therapies are investigational and offered under regulatory frameworks outside the US.
Explore Minicircle's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.